Glycosylation-mediated inhibition of factor X
US6117836A · kind A · utility
0Cited by
7References
2Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 2, 1994 |
| Grant date | Sep 12, 2000 |
| Priority date | — |
| Expiry date | Dec 2, 2014 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S436/827
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Reagents that specifically bind a carbohydrate target wherein sialic acid is linked at the nonreducing terminus of a glycoside to a galactose or galactosamine residue through an .alpha.2-6 linkage are able to inhibit the conversion of human Factor X to human Factor Xa. These reagents (SA/Gal/GalNAc binding reagents) as well as other strategies for inhibiting the conversion of Factor X to Factor Xa are useful in treating thrombosis, inflammation and other conditions associated with excess thrombin activity.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.